Pseudouridine and 1-ribosylpyridin-4-one-3-carboxamide (PCNR) serum concentrations in human immunodeficiency virus type 1-infected patients are independent predictors for AIDS progression

Journal of Infectious Diseases

Volumn 174, Issue 1, 1996, Pages 199-203

  Intrieri, Mariano ^b   Calcagno, Giuseppe ^b   Oriani, Giovannangelo ^b   Pane, Fabrizio ^b   Zarrilli, Federica ^b   Cataldo, Pietro Tullio ^b   Foggia, Maria ^b   Piazza, Marcello ^b   Salvatore, Francesco ^a   Sacchetti, Lucia ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 RIBOSYLPYRIDIN 4 ONE 3 CARBOXAMIDE; BETA 2 MICROGLOBULIN; NUCLEOTIDE; PSEUDOURIDINE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; DIAGNOSTIC ACCURACY; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD;

EID: 19244364986     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.1.199     Document Type: Article

References (15)

1. Levy JA. HIV pathogenesis and long-term survival. AIDS 1993;7:1401-10.
2. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 1995;267:483-9.
3. Easterbrook PJ, Emami J, Gazzard B. Rate of CD4 cell decline and prediction of survival in zidovudine-treated patients. AIDS 1993;7:959-67.
4. Saah AJ, Hoover DR, He Y, Kingsley LA, Phair JP, the Multicenter AIDS Cohort Study. Factors influencing survival after AIDS: report from the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1994;7:287-95.
5. Lagakos SW. Surrogate markers in AIDS clinical trials: conceptual basis, validation, and uncertainties. Clin Infect Dis 1993;16(suppl 1):S22-5.
6. Russo T, Colonna A, Salvatore F, Cimino F, Bridges S, Gurgo C. Serum pseudouridine as biochemical marker in the development of AKR mouse lymphoma. Cancer Res 1984;44:2567-70.
7. Esposito F, Russo T, Ammendola R, Duilio A, Salvatore F, Cimino F. Pseudouridine excretion and transfer RNA primers of reverse transcriptase in tumors of retroviral origin. Cancer Res 1985;45:6260-3.
8. Pane F, Intrieri M, Calcagno G, Izzo E, Salvatore F, Sacchetti L. Diagnostic and discriminatory efficiency of eight serum modified nucleosides in HIV infection and in at-risk subjects. J Liquid Chromatogr 1993;16:1229-48.
9. Pane F, Buttò S, Gobbo ML et al. Direct detection of proviral gag segment of human immunodeficiency virus in peripheral blood lymphocytes by colorimetric PCR assay as a clinical laboratory tool applied to different at-risk populations. J Clin Microbiol 1995;33:641-7.
10. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS in adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41(RR-17):1-13.
11. Gehrke CW, Kuo KC. Ribonucleoside analysis by reversed-phase high-performance liquid chromatography. J Chromatogr 1989;471:3-36.
12. Pane F, Savoia M, Fortunato G, et al. Serum pseudouridine in the diagnosis of acute leukemia and as a novel prognostic indicator in acute lymphoblastic leukemia. Clin Biochem 1993;26:513-20.
13. Rasmusson T, Bjork GR, Hietala SO, Stenling R, Ljumberg B. Excretion of pseudouridine as an independent prognostic factor in renal cell carcinoma. Acta Oncol 1991;30:11-5.
14. Millis GC, Davis NJ, Lertratanangkoon K. Isolation and identification of 1-ribosyl pyridone nucleosides from human urine. Nucleosides Nucleotides 1989;8:415-30.
15. Speer J, Gehrke CW, Kuo KC, Waalkes TP, Borek E. tRNA breakdown products as markers for cancer. Cancer 1979;44:2120-3.